

Appl. No. 08/704,159
Reply to Office action of August 25, 2004

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-112. (Cancelled)

113. (Currently amended) A method of making a soluble botulinum toxin comprising:

expressing a botulinum toxin ~~type-A~~ from a prokaryotic expression vector comprising a botulinum toxin ~~type-A~~ nucleotide sequence in a prokaryotic host cell wherein the prokaryotic expression vector includes a weak inducible promoter relative to a T7 promoter thereby making a soluble botulinum toxin ~~type-A~~.

114. (Previously presented) The method of claim 113 wherein the prokaryotic host cell is E. coli.

115. (Previously presented) The method of claim 114 wherein the E. coli is strain BL21 (DE3).

116. (Previously presented) The method of claim 115 wherein a pLys gene is included in the host cell.

117. (Previously presented) The method of claim 116 wherein the pLys gene is plasmid encoded.

118. (Cancelled)

Appl. No. 08/704,159
Reply to Office action of August 25, 2004

119. (Cancelled)

120. (Previously presented) The method of claim 119 wherein the inducible promoter is a T7lac promoter.

121. (Previously presented) The method of claim 113 wherein the host cell includes a lacIq gene.

122. (Cancelled)

123. (Cancelled)

124. (Previously presented) The method of claim 113 wherein the botulinum toxin nucleotide sequence specifically hybridizes under highly stringent conditions to SEQ ID NO:27.

125-134 (Cancelled)

135. (New) The method of claim 113 wherein the botulinum toxin is type A.